GBT - Global Blood Therapeutics Inc.
32.01 +0.01 (0.04%)
After hours: 4:11PM EDT
| Previous Close | 32.45 |
| Open | 32.20 |
| Bid | 31.50 x 300 |
| Ask | 33.00 x 100 |
| Day's Range | 31.25 - 32.45 |
| 52 Week Range | 13.35 - 41.15 |
| Volume | 929,869 |
| Avg. Volume | 774,061 |
| Market Cap | 1.4B |
| Beta | N/A |
| PE Ratio (TTM) | -13.02 |
| EPS (TTM) | -2.46 |
| Earnings Date | Nov 7, 2017 - Nov 13, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 57.09 |
- GlobeNewswire•8 days ago
Global Blood Therapeutics Announces Presentation of New Data Showing Positive Effect of GBT440 on Sickle Cell Disease Patient with Variant Genotype
First Presentation of Data Specifically Focused on HbSC Genotype. Data Presented at Academy for Sickle Cell and Thalassemia 11 th Annual Conference. SOUTH SAN FRANCISCO, Calif., Oct. 11, 2017-- Global ...
- Investor's Business Daily•15 days ago
Global Blood Therapeutic Earns Relative Strength Rating Upgrade
A Relative Strength Rating upgrade for Global Blood Therapeutic shows improving technical performance.
GuruFocus.com•15 days agoSteven Cohen Doubles Down on Sickle Cell Disease Therapeutics Company Global Blood
Guru adds approximately 225% to the position
- GlobeNewswire•16 days ago
Global Blood Therapeutics Announces Upcoming Presentations of GBT440 Data at Two Sickle Cell Disease Meetings in October
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2017-- Global Blood Therapeutics, Inc. today announced that new data supporting its GBT440 program in sickle cell disease will be presented in October at the Academy ...
- GlobeNewswire•23 days ago
Global Blood Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2017-- Global Blood Therapeutics, Inc. today announced that on September 25, 2017, the compensation committee of the Company’ s board of directors granted one new ...
- Simply Wall St.•28 days ago
One Thing To Consider Before Buying Global Blood Therapeutics Inc (GBT)
For Global Blood Therapeutics Inc’s (NASDAQ:GBT) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. Broadly speaking,Read More...
- Investor's Business Daily•last month
Global Blood Therapeutic Sees IBD RS Rating Climb To 71
Global Blood Therapeutic shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
- GlobeNewswire•last month
Global Blood Therapeutics To Convene Sickle Cell Disease Influencers at Annual Sickle Cell Disease (SCD) Therapeutics Conference
Healthcare Providers, Patient Advocates, Government Agencies and Industry Will Discuss Critical Issues Facing SCD Community During National Sickle Cell Disease Awareness Month. Livestream of Conference ...
- GlobeNewswire•last month
Global Blood Therapeutics Receives Rare Pediatric Disease Designation from FDA for GBT440 for Treatment of Sickle Cell Disease (SCD)
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2017-- Global Blood Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has granted Rare Pediatric Disease designation to GBT440 for the ...
- GlobeNewswire•2 months ago
Global Blood Therapeutics Announces Upcoming Participation in Multiple Investor Conferences in September
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2017-- Global Blood Therapeutics, Inc. today announced that it will present at the following investor conferences in September:. 12 th Annual Wells Fargo Securities ...
- GlobeNewswire•2 months ago
Global Blood Therapeutics Announces Participation at the 2017 Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2017-- Global Blood Therapeutics, Inc. today announced that it will present at the 2017 Wedbush PacGrow Healthcare Conference in New York City on Wednesday, August ...
- Associated Press•2 months ago
Global Blood reports 2Q loss
The South San Francisco, California-based company said it had a loss of 55 cents per share. The results surpassed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment ...
- GlobeNewswire•2 months ago
Global Blood Therapeutics Reports Recent Business Progress and Provides Second Quarter 2017 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2017-- Global Blood Therapeutics, Inc. today reported business progress and financial results for the second quarter ended June 30, 2017.. "Regulatory authorities ...
- GlobeNewswire•3 months ago
Global Blood Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., July 26, 2017-- Global Blood Therapeutics, Inc. today announced that on July 24, 2017, the compensation committee of the Company’ s board of directors granted one new employee ...
- Zacks•4 months ago
Implied Volatility Surging for Global Blood Therapeutics (GBT) Stock Options
Global Blood Therapeutics (GBT) warrants investors' attention based on moves in the options market lately.
- TheStreet.com•4 months ago
Global Blood Shares Pop on Priority Designation; Kite Pharma Rises on Patent News: Biotech Movers
Global Blood Therapeutics, Kite Pharma and Bellicum Pharmaceuticals were among the biotech movers in premarket trading on June 28.
- Associated Press•6 months ago
Global Blood reports 1Q loss
The South San Francisco, California-based company said it had a loss of 60 cents per share. The results surpassed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment ...
- Investopedia•7 months ago
5 Top Performing Stocks of the Best ETF of Q1
After being stressed by the twin attacks of higher drug pricing and increased regulatory scrutiny, the biotech sector has made a strong comeback in the first quarter of 2017. In fact, BioShares Biotechnology ...
